The DMTN Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the dematin (DMTN) gene. This product consists of a heterogeneous pool of A2780 cells harboring gene disruptions at the DMTN locus introduced by CRISPR/Cas9-mediated genome editing, resulting in a functional knockout model without clonal isolation. The polyclonal format reflects a population-level gene knockout, providing a robust tool for studying dematin??s role in cytoskeletal regulation and membrane stability.
The A2780 cell line is a widely used epithelial model of human ovarian carcinoma, originally established from an untreated patient with ovarian endometrioid adenocarcinoma. These adherent cells retain characteristics of ovarian carcinoma and serve as a standard platform for investigating ovarian cancer biology, including tumor progression, metastasis, and drug resistance. The A2780 background provides a clinically relevant context for exploring the functional impact of DMTN loss in an ovarian cancer setting.
DMTN encodes dematin, an actin-binding protein that functions as a critical regulator of the actin cytoskeleton. Dematin exists in a phosphorylated state regulated by upstream kinases such as cAMP-dependent protein kinase and protein kinase C, and is activated downstream of RhoA GTPase signaling. It directly interacts with and crosslinks actin filaments, and also binds to spectrin, adducin, band 4.1, and the glucose transporter GLUT1, thereby linking the cytoskeleton to the plasma membrane. Through these interactions, dematin influences membrane mechanical stability, actin network organization, and cellular processes such as shape control and adhesion. The knockout of DMTN disrupts these protein-protein interactions, leading to alterations in actin cytoskeleton dynamics, membrane integrity, and potentially downstream signaling pathways involving RhoA.
In the A2780 ovarian carcinoma model, DMTN knockout is expected to perturb cytoskeletal architecture, affecting cell morphology, migration, and invasion??processes critical for ovarian cancer metastasis. Dematin??s role in anchoring the spectrin?Cactin network to the membrane suggests that its loss could compromise membrane stability and alter signal transduction from cell?Cmatrix adhesions. Furthermore, by modulating the trafficking or activity of GLUT1, dematin may influence metabolic adaptations in cancer cells. Thus, this knockout model offers a valuable system for dissecting the contributions of cytoskeletal-membrane coupling to ovarian cancer cell behavior and therapy resistance.
These polyclonal knockout cells are suitable for a range of functional assays, including wound healing migration assays, Matrigel invasion assays, and immunofluorescence staining for F-actin to visualize cytoskeletal rearrangements. Protein-level confirmation of DMTN disruption can be performed via Western blotting. The model also supports drug sensitivity profiling to assess the impact of dematin loss on chemotherapeutic response. Beyond ovarian cancer, the cells can be applied to studies of hereditary spherocytosis and elliptocytosis, where dematin mutations are implicated. For further technical details, please contact Ascent Research.
